Ocata Therapeutics Inc fka OCAT

[rocky301]

I was aware that Biotime had acquired the ACTCellerate exclusive license last July but was unaware a month later Biotime acquired
"iPS and Embryonic Stem Cell Differentiation Technology" from ACTC.
http://www.embryome.net/breakingnews/BioTimeiPS8-21-08.pdf

Biotime Pr'd the event and did an 8K but nothing from ACTC's side that I am aware of. Another joy of ACTC not reporting. Our ex-CEO has developed a large IP portfolio, through ACTC, at a maximum cost of approx. $2MM. I realize these transactions took place when ACTC was at their low but it still has me scratching my head. Hoping all this doesn't bite them in the arse. Conference call listed below is worth a read, imo.

(Biotime)
IP property list via ISCO(ALL WARF and ACTC)
http://embryome.net/iprop.htm

(ACTCellerate)
ALAMEDA, CA, July 16 , 2008 – Embryome Sciences, Inc., a wholly owned subsidiary of BioTime, Inc., (OTCBB: BTIM) has acquired from Advanced Cell Technology, Inc. (“ACT”) an exclusive license to use “ACTCellerate™”embryonic stem cell technology and a bank of over 140 diverse progenitor cell lines derived using that technology.
Embryome Sciences will pay ACT a $250,000 license fee and an 8% royalty on sales of products, services, and processes that utilize the licensed technology. Once a total of $1,000,000 of royalties have been paid, no further royalties will be due.
http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6046844

(August 15th, 2008)
BioTime, Inc. ’ s Subsidiary, Embryome Sciences, Inc., Licenses Virus-Free iPS and Embryonic Stem Cell Differentiation Technology
Under the ACT License, Embryome Sciences will pay ACT a $200,000 license fee and an 5% royalty on sales of products, services, and processes that utilize the licensed ACT technology, and 20% of any fees or other payments (other than equity investments, research and development costs, loans and royalties) received by Embryome Sciences from sublicensing the ACT technology to third parties. Once a total of $600,000 of royalties has been paid, no further royalties will be due.
http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6116281

(Conference Call 8k)
Patents were filed or licensed by Advanced Cell Technology on iPS technology, and one patent in particular (PCT/US2006/030632) describes the use of the four genes OCT4, SOX2, NANOG, and LIN28 to reprogram human cells, and was filed approximately two years before the first published reports of iPS. We were happy to announce on August 21 of this year that we obtained two licenses to this family of patents for many human therapeutic uses. These licenses permit us to use a bundle of stem cell technology, including the right to use patent (PCT/US2006/030632) in conjunction with other licensed technology. The licenses were obtained on terms very favorable to BioTime.